J <\/p>\n
ust under a year ago, Veritas Genetics announced it would be launching the firstwhole genome sequencing test with a price tag under $1,000. Now, the company isbringing on board a new vice president of clinical affairs to help lower the cost of that sequencing and improve the process of interpreting the results. <\/p>\n
Birgit Funke has worked extensively on the genetic underpinnings of inherited heart diseases, including cardiomyopathies, and has also written about the racial disparities in genetic testing and research. As of February 1, Funke hassplit her time between theDanvers, Mass.-based spinoff of the non-profit Personal Genome Project and her work as an associate professor at Harvard Medical School and a researcher at Partners Personalized Medicines Laboratory of Molecular Medicine. <\/p>\n
This is a STAT Plus article and is only available to STAT Plus subscribers. To read the full story, subscribe to STAT Plus or log in to your account. Good news: your first 30 days are on us. <\/p>\n
Kate Sheridan can be reached at kate.sheridan@statnews.com<\/a> Follow Kate on Twitter @sheridan_kate <\/p>\n <\/p>\n Read more: <\/p>\n Startup Spotlight: Seeking to improve the $999 genome for consumers - STAT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" J ust under a year ago, Veritas Genetics announced it would be launching the firstwhole genome sequencing test with a price tag under $1,000. Now, the company isbringing on board a new vice president of clinical affairs to help lower the cost of that sequencing and improve the process of interpreting the results Continue reading